NGS-based Tissue-Blood TMB Comparison and Blood-TMB Monitoring in Stage-III Non-Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy

This study suggests that in patients with LA-NSCLC, b-TMB is a reliable biomarker, and its dynamic monitoring can help distinguish patients who might benefit most from the consolidated immunotherapy.PMID:38390854 | DOI:10.1080/07357907.2024.2316297

Source: Cancer Investigation - February 23, 2024 Category: Cancer & Oncology Authors: Luxi Ye Xiao Chu Jianjiao Ni Li Chu Xi Yang Zhengfei Zhu Source Type: research